硼替佐米和柔红霉素联合应用对多发性骨髓瘤细胞株KM3的作用(英文)

Combined Effects of Bortezomib and Daunorubicin on Multiple Myeloma Cell KM3 In Vitro

为了研究硼替佐米(bortezomib,Bor)单用及与柔红霉素(daunorubicin,DNR)联合应用对多发性骨髓瘤(multiple myeloma,MM)细胞株KM3细胞的抑制作用,采用MTT法检测Bor单用及与DNR联合应用对KM3细胞的抑制作用,求出其IC50。结果表明:Bor、DNR对KM3细胞生长抑制作用呈浓度依赖性,IC50分别为0.27μmol/L,0.16μmol/L;Bor联合DNR对KM3细胞生长抑制作用明显增强(p<0.05)。结论:在体外,Bor联合DNR对KM3细胞生长抑制有协同作用。

The aim of this study was to investigate the combined effects of bortezomib （ Bor ） and daunorubicin （DNR） or each drag alone on proliferation of human multiple myeloma cell line KM3. KM3 ceils were cultured with different concentrations of Bor and DNR, Bor or DNR alone for different times. The cell proliferation was analyzed by MTT assay, and the concentration of 50% growth inhibition（ IC50 ） was calculated. The results indicated that both of Bor and DNR inhibited KM3 cell proliferation in dose dependent manner. The IC50 of both drugs were 0.27 μmol/L and 0. 16 μmol/L respectively. The inhibiting rate of Bor plus DNR on KM3 cells was much higher than that of Bor （p 〈 0.05 ）. It is concluded that the Bor has synergistic inhibitory effect with DNR on the growth of KM3 cell in vitro.